Alethio Therapeutics
Alethio Therapeutics

Alethio Therapeutics

Measured by AhrefsDR6Ahrefs DR: 6/100. Bottom 25%. Measured by Ahrefs. Median 44.Measured by StartupHub.aiAgent45Agent Readiness: 45/100. Above median. Measured by StartupHub.ai. Median 41.Measured by Google PageSpeedSpeed74Site Speed: 74/100. Above median. Measured by Google PageSpeed. Median 62.Measured by StartupHub.aiTrust60Data Trust: 60/100. Below median. Measured by StartupHub.ai. Median 61.

Biopharmaceutical company developing next-generation therapies for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers.

2021ActiveOxford, United Kingdom

About

Alethio Therapeutics is a biopharmaceutical company focused on developing targeted, next-generation therapies designed to selectively eliminate disease-driving cells in myeloproliferative neoplasms (MPNs) and modify underlying disease progression. The company leverages its ARTEMIS discovery engine, which integrates patient-derived data, advanced 'omics, machine learning, and organoid models, to identify and validate novel targets for these blood cancers.

Key facts

Website
alethiotherapeutics.com
Headquarters
Oxford, United Kingdom
Founded
2021
Total funding
$90M (Series A)
Business model
B2B

Funding rounds

Funding rounds raised by Alethio Therapeutics
DateRoundAmountLead investors
1 Nov 2026Series A$90MSofinnova Partners, RA Capital

Tech stack

Detected on alethiotherapeutics.com, last scanned 6 Nov 2026.

Hosting
Google Cloud
Email provider
Microsoft 365
Run your own scan

Test your Ahrefs DR

The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.

Write the first review

Frequently asked

Is Alethio Therapeutics trustworthy and reputable?

StartupHub's Data Trust & Reputation score for Alethio Therapeutics is 60 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has Alethio Therapeutics raised?

Alethio Therapeutics has raised a total of $90M in funding. The most recent round on record is Series A.

SEC filings, insider activity, nonprofit links and pay benchmarks for Alethio Therapeutics:

Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules